TMCI - Earnings call transcript Q2 2024 | Treace Medical Concepts, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Treace Medical Concepts Second Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Vivian Cervantes, Gilmartin, Investor Relations. Please go ahead.

Vivian Cervantes

welcome second and conference XXXX everyone, call. afternoon, to quarter our earnings Good company John will Officer; from today Participating the be Hair, Financial and Chief Treace, Officer. Mark Executive Chief

commercial detailed review our John commentary will market During released financial of by closed the a on today. second call, our for Mark activities, results offer after quarter followed

We a question-and-answer will session remarks. host following our prepared

be website release archived at of the of Investor press Relations recorded section in and the can being in found will This Investors our investors.treace.com. our be call is Our section website.

that like our statements. begin, we statements of predictions remind we estimated forward-looking will is XXXX. as Private Before and relate it events today's Reform are future statements in during intent would be trends results to forward-looking to all expectations Litigation as you the performance well under of Securities that or that or market protected call our Act made Any

full now on to Accordingly, filed With that, quarter today our reliance should XXXX our you call are of a turn statements risks. implied no events are Treace not refer on for statements differ place current forward-looking forward-looking results XX-K upon based the or those and over detailed filed to XXXX, current risks estimates forward-looking the All second assumes statements. and could for these and the actual available based that obligation or these to Form anticipated for Please material statements. year Medical All to uncertainties these from undue update I February John. statements. SEC presentation Form involve XX-Q filings, information, XX, assumptions. cause our These by materially upon including our statements various and

John Treace

expected. afternoon, call. pleased as for Good and quarter Vivian. conference report second our us joining quarter you, came to that in We're XXXX second earnings you the on thank Thank everyone,

as leveraging continues broadening bunion presence During significant new in products relatively the which at several market, the doctors patients progress to of our enter leadership osteotomy over invasive with user prepare position minimally in made interest grow alike. commercializing and Lapiplasty surgeon aimed to our base quarter, we customers we and one nascent, market, market the towards X,XXX

focused new accelerate in have penetration and U.S. that and we total throughout an of platforms, on we full the our technologies bunion to developing MIS of new pipeline XX to engine back $X more and of our XXXX delivering osteotomy R&D active addressable commercialize complement market. a Inclusive have XXXX. of starting We than new billion-plus expect half products

quarter. the to Turning

revenue during evolving Lapiplasty broad and Adductoplasty and to suite powerful of direct delivered provide will surgeons bunion second address a increase comprehensively product favorable performed X% revenue $XX.X was representing trends, surgical the offerings, resulted become mix are resulted active fashion products, surgeon higher clear quarter. believe products, in procedure we quarter from fourth share introduce our quarter surgeon along million, over these base with in MIS as our which driven Growth volumes base, alike. and of by growth focused patients of see from sales by force, a customer our system other as complementary well new in revenue Second cases the technologies case. of SpeedPlate, on an expected our increases our the to new which opportunities of continued we XXXX. We Building needs in and these broadening Adductoplasty adoption to available flagship per osteotomy our limited as bunion growing expand

osteotomies to we using of estimate procedure around XX% overall the the U.S. limiting technically osteotomies. challenging the believe adoption osteotomies MIS are by surgeon bunion of operation, techniques. comprised is broad bunion thus we and Fusion surgery volume and the MIS patients XX% and predominantly in surgeons Notwithstanding market in approximately a from foot MIS the increasing remains community. Lapidus XX% performed alike, freehand ankle interest Today, XX% And and

foot the example, we this osteotomy more introduce market stated And highly X proficiency. doing that expand surgeons For to build some plan the be new and It's believe procedure as for reproducible we minimally procedures reproducible strategy as where doing the upon capabilities achieve of XD cases invasive osteotomy broad This XX% of freehand that expand the today. XX% by and more we high allowing segment current XD in so, MIS approaches bunion or learning XD have a core correction achieve instrumented approximately accessible surgeons to in overall to corrections. backdrop curve Lapidus and community. Lapiplasty MIS our with ankle playbook, simplifying can to market reproducible, so, the market from these can XX segment helped or And follows systems. for in surgeon MIS the Lapidus we osteotomies the made to XXXX challenging

us capture, total base surgeon nearly XX% average, XX% average their annual which tenured our to pride to mix. of annual surgeon cases, allowed most our By take bunion something is more of customers, than we X,XXX This closer cohorts our is has for said, on bunion estimates, of great case Lapiplasty in. Lapiplasty

bunion osteotomy can Given Lapiplasty, but X this, our solutions. with we into MIS the procedures forthcoming our remaining with believe not we XX% penetration also their accelerate of only

attract exposed of meaningful also osteotomies have yet metatarsal been to today new We patients opportunity have not to bunion on such, believe their as who customers and, rely vast surgeon a Lapiplasty. the for we majority

some our MIS additional me share osteotomy forthcoming you with solutions. X color Let on

a to experienced allow patients weight-bearing opportunity with in bunion pain. surgeons. ankle this team Our first cosmetically rapid and post-op swelling, recognized correction resolve X.X-centimeter through to designed internationally lifestyle-limiting conjunction patients. for the we a their incision Nanoplasty translate and specialized less And return it surgical small pain features on consistent minimally making boot to can the refined delivered of and system a foot MIS side is to other or foot, procedures, a System for highly as offer highly shoe. Nanoplasty with known a discrete the bunion reproducible invasive importantly, less XD the appealing in believe implant It patients instrumentation and was developed of with

of by based to emerging We have approach on And already feedback, believe of their bring of a disrupt bunion ultimately this to dramatically our positive patients. segment procedure greater we allowing market significant cohort reducing surgeon their strong our the surgeons on can curves, number and more Nanoplasty trained surgeons benefits a the Nanoplasty surgical System. MIS learning simplifying

towards of MIS their MIS base Our is offering screws metatarsal fixation second for osteotomies. more osteotomy in existing geared use surgeons who established foot

the is reproducible XD and offer corrections. here approach market, segment method achieve their instrumented to to Our this an bunion of existing

of XD proud developments We evolving coupled MIS the XD these that to of meet systems, are a and and solutions instrumented with of our provide these surgeons their believe MIS X System preferences comprehensive suite patients. Micro-Lapiplasty new

configuration commercially pleased midfoot users. for from we're half now configuration larger software-driven a in excited Mini-Adductoplasty preoperative foot. deformity offerings, of patient-specific SpeedPlate to bunion cut the is by offers We're that announce other also the instrumentation, slated for new Adductoplasty which procedure size second designed available, new midfoot incision include deformity and In and surgeon receiving addition corrections already our and MIS introductions to is product XXXX, System. correction This midfoot which bones this reduces and instrumentation, about fusions these for Point planning of which excellent SpeedPlate the we're related XX%. patient-specific our next-generation correction guides Red feedback

XX expected with cadence through our of introductions discussed the We're excited and to have inclusive of as growing these bring team X,XXX-plus we a direct today, active products established in sales force pipeline innovations continue than expand to footprint innovations to the we active our an foot new through base new our here of more we steady market. surgeons Further, ankle of full R&D for a XXXX. slated

our to Turning outlook. financial

are X% which revenue. of XXXX reaffirming our We million, to XXXX over $XXX increase to revenue reflects million year XX% of an full $XXX guidance

clinical mini-incision clinical market Lapiplasty From data, presenting with on data coming well flagship adoption procedure. the Orthopaedic data we call Mark we both Before see continue be growing me for for clinical key driver as of evidence, Foot study the industry our our X-year of & with and reinforcing and Lapiplasty a report a at and of we to forward reimbursement. believe we Lapiplasty and ALIGNXD review Ankle of can our performance, in marketplace, patients. our to XXXX as business to communities ALIGNXD Society what only look the Meeting resonates provide which participant surgeon A our study in believe from American our on patient out we body our to the commitment surgeons upcoming believe clinical differentiating financial let September. over resonate first further update turning data interim is alike, our with studies an the We patient differentiated

for Finally, Medicare hospital procedures, released as used surgical and its know, services case. of including in you surgical implants proposed rates for outpatient ASC recently and cover the to XXXX many supplies CMS facility costs payment

increase As well-established a used CMS Fusion used $XX,XXX see APC increase This XX% XXXX code proposing is to proposed to represents to proposed setting, the in In in an outpatient XXXXX we're procedures or for XX% codes, rate XXXX. a covered products XXXX CPT specific payment for reminder, XXXX. reassign that of of of ASC hospital XXXX. is an over CPT compared by $X,XXX, with or $X,XXX primary a the are $X,XXX our pleased procedure to and Lapidus the code Lapiplasty

For are and digits to codes ASC to XXXX other Treace single proposed outpatient hospital bunion increase rates and related relevant Medical, Medicare the the reimbursement low reimbursement proposed for settings.

often expected on these this finalized commercial remind patient subject estimate change. you not rates to while the we of proposed to which demographic rules, are encouraged insured, commercially we our are influence majority that payers. have be development, November are therefore, until to While Medicare And be and by we

now review to me call Mark turn performance. over to our Let Mark? the financial

Mark Hair

increases adoption over technology to Thank in prior surgeon increases margin compared an the XX.X% you, of was increases quarter in to partially The other of XX.X% of and due as $X.X was was by active Growth product well by everyone. and due decrease of rates. second SpeedPlate XXXX. offset as goods cost the product favorable year. changes volumes, $XX.X quarter our was royalty John. of quarter other and million revenue our in in X% Gross in XXXX increase Revenue second sold, lower in afternoon, mix, to case expanding the complementary mix second driven the Good million, products primarily base.

the were the gross margin Second in second We gross unchanged support investments in of margin commercial initiatives. other was in of Total XXXX. XXXX product our in for XX.X% expenses expenses the of expenses quarter quarter QX. in sales XXXX. and Total XX.X% investments $XX.X from direct were expanding The strategic second operating in operating $XX.X operating million reflects million reported quarter channel, increase innovation

stockholders common $XX per period securities share $XX.X of and loss million $XX.X million to attributable receivable investments marketable same of were was cash the and share million equivalents Second or $X.XX loss a quarter XXXX. net net of or XX, Cash, June XXXX. as compared per to $X.XX for

to concluding, Before turn for me year our the let full XXXX. outlook

of are guidance which X% $XXX over an As revenue full John XX% revenue. $XXX XXXX mentioned, million to reaffirming to of we year increase million, XXXX reflects

XX% also XXXX. to year the For XXXX, expect back year to turn With continue full to compared let the EBITDA John. full call adjusted approximately we me that, improvement the of

John Treace

U.S. clear we XD have X,XXX customer total summary, and growing solutions surgeon focus bunion here users market. team a a a at with billion-plus exceeding In Mark. comprehensive with on addressable a a building company base large Treace Thanks, $X dynamic

is scalable and interest specialized invasive minimally a team from base into market focused our bunion sales accelerating the alike. the patients large relatively have customer with nascent our also leveraging model experiencing forthcoming segment, into direct-focused entry osteotomy and penetration business by on that growing We and surgeons one our

our open solutions the the reproducible reasons, to of line evolving continuing the we the let your For these address to to for bunion pipeline expand ankle to uniquely call footprint market to patients With an positioned the deliver comprehensively alike. believe me over and needs foot of exciting operator we're by that, in questions. and surgeons turn differentiated now

Operator

with Marcus JPMorgan. our Instructions] comes first And question Robbie [Operator from

Lilia-Celine Lozada

This Lily for on actually is Robbie.

$X million reiterating million, about by you're guidance. consensus to beat You but $X

that Or just at the dynamics what is would the there and conservatism? are for be half? thoughts of implies that the Any color year in helpful. half on So play the other second your back on guide

Mark Hair

Mark. question. the is for thanks Lily, This

what happened QX QX, in came results came as expected. As we at really -- look in

far, so forecast. to is And QX tracking

a got receive the continue organization from to We good we've coming really things sales how our about. and updates are that field on handle believe and

and And didn't it we last hasn't that not so we guidance that changed -- just really much long. been think since there's time our has changed that the

really good feel just about the time. So guidance we last gave that we

Lilia-Celine Lozada

you. Got

have but follow-up, through new physician have competition update? last count now not anymore, and how Okay. out utilization can to you qualitatively a well on And and able And trending been you're kits those the regularly just pieces since in market? the as gave I you appreciate how increased doc talk right adds breaking with drive an been direction us you

Mark Hair

Yes, this is Mark.

me respect we're on first stab to and John have Let certain with the some prepared over X,XXX John at But take remarks count, maybe right now. color. mentioned additional a that, that our surgeon customers will

year. So ] about that million or the of implies first [ the $XXX in so half

to back more hand, the of we'd in full expect the about in get first year, so of million for half probably tend adds $XXX $XXX somewhere already year. the So said year, million that one the in to ] on surgeon we half million we [ the between $XXX

we're track. like feel really we on So

to over the a this events weekend. our We've there. one packed a national continue house up, interest We of got a all lot education We've country. coming see in event got

And to They continue so our They technology. they Lapiplasty. attract our we training and using come events new up come end to for surgeons.

that. to users. to we're feel for new do on So this like We surgeon we'll year course add continue

thought utilization, quarter. we a for change really to that happen. that a not really utilization customer And much feel changed identified really that about we QX what base. of forecast last since somewhat talked to to has able going on respect what With right we good in were happened in certain was we We

expected, tracking as is and as QX QX well. came in so And

we believe update identified there that last So quarter. to trends we really hasn't an been the that

Operator

And with Danielle Antalffy from next our comes question UBS.

Danielle Antalffy

Just be won't speaking, call. minimally directionally guidance new this a on as you the guys acceleration XXXX I headwind of just question, a of XXXX XXXX? like invasive And lot a could I you have we give look of appreciate make mean, there that John, perspective specifically a a launches year guess, is think it product ahead, osteotomy. missing we these coming, is right little But something as more product might Or here I to new growth given launches? look XXXX from bit

Mark Hair

going John, color. that take again, love is additional then stab a have this Danielle, I'm Mark. I first and may the at But to question. some

into opportunity You hear probably this in as growing several new some our base. John's the large can of about having enthusiasm customer great voice we're products talking

about right in products for have X,XXX very position direct surgeons on guidance over now XXXX, that And that. to will excited impact so certainly really a but we believe provide sales these are trajectory. top channel We're our we not line a definitely positive all new to our delivered by

to mentioned, are is products John new force customers asking our for and our As ready deliver. more sales

only impact the said, they're getting of available on forward as to quantities to updates what at look light we more really QX. in John going start we're can And as our business. So our progress. future reiterate end the to We just to talk QX as in into providing QX again, products how will be far new

lot year, see having but definitely this it of impact impact greater a next not a year. we So

Danielle Antalffy

we then the saw from still a change some extent, Understood. I out to a the that the or saw dynamics been similar what increased the may in competitive I perspective. just due pressures to or have to quick perspective competitive devices. from any And front mean trialing competitive follow-up docs just QX different on trying of you there? mean,

John Treace

small, it's knockoffs question. multiple competitor, Yes, private, Lapiplasty. back last but pretty public the with not Thanks in offering John. call of May. really It's Danielle, It's our consistent for one big,

format don't sales really and we've team osteotomy this and customer a got is products Mark dialed the highly of for analytics, winning team into as which progress from Like through strong said, events, this This enhanced well share of a broadening this our for for we're greater the come now really we Some with armed surgeon and that Nanoplasty events, our on Mini-Adductoplasty, the offer But in a of are versatile with into late been really sales today. attention Micro-Lapiplasty, we platform. as SpeedPlate a has us. our as our cases they're surgeon And getting line those customers excitement It's home, with demand and medical education of our bunion Nanoplasty that to year focused technologies drive and to System. for attendees great them our MIS we're year. includes there XXXX. they go lot on new in generating test the waiting systems surgeons

to namely next their PSI and team ready our the maximize months, of on getting catalyst, going customer in product in will lot sales base our cases systems MIS that Point share a QX. the while for ground customer over our next and the we're start So Red several

Operator

our And Ranieri Drew with Morgan next from question Stanley. comes

Andrew Ranieri

give what to from I seeing was Mark that if maybe start. Mark, goes just just of market competitive talk growth guidance, about asked, just you're know week the mean market, -- here? but Maybe procedure questions types that a in you're ankle wondering and mainly softness to signaled that and seeing expectations you could on your market a last standpoint, back there's foot. for procedural was just I the you're -- you this in kind getting reiterated, of foot of perspective to kind we and I there but the reaffirmed I what know John, maybe from us your competitor

John Treace

the mounting Mark first them QX, softening a knockoffs identified of take Lapiplasty and at me our can that that I that, in a in We in trialing saw predominantly in first -- expect, we're some but of the operate I'll to we Mark headwinds as did change half as new of and you player pretty But I about play anything it as trends Mark, say as add to like more causes time would guidance good fill that. at we or... it that saw same we well. early they don't said, that April, not and they that's large I'd tracking to that we increasing saw identified a time. that guidance, soft Dialing resulted well. customers osteotomies. comprehensive aware that know time, late think and they towards here. these is said aren't of as job We the just kind Drew, MIS continuing and to we at generating spoke those say and at interest we that to want clearly some May. causes, in and QX through behind am us stab identified Yes, back continue the called from

Mark Hair

Yes, I'd agree.

talked that last that As comps of this there's year half toughness the but there into we in about we that for us. second knew our quarter, back quarter, be some guidance would coming better

so opportunity And QX in the increased growth and to have rates both QX.

and statements forward and still we to QX look behind prior stand So those QX.

Andrew Ranieri

to in the just touch a guidance can you're maybe of And year next terms there little be for we Mark, there XX% should for as great. you getting profitability And what would just Just the improvement. think this more give of leverage bit expecting detail any breakeven operating I'll but on breakeven? reaffirmed for details ask anyway, year? closer or more to just

Mark Hair

question. the question your Yes. I first. I'll Thanks, Drew. start appreciate with last And Maybe

the healthy First we a line, get improvement bottom want can the of through We all, adjusted we EBITDA. really year. make believe this to in that

with new XX%. can do we our We that. it's so next into products, that with absolutely growth believe year And continued

So next EBITDA-positive we year. forward look to being

force, been the growing are that revenue build with done. the company team. of don't the achieve had build grown as the we in large We've a a to much a ranges invest natural that into So and higher lot to leverage, the their a the done to of is as more some lot with longer force, some productive in and talked as A have very they We've we've customers. building there's past leverage they sales with about and somewhat with need we've company. get we've certain the We things business. maturer really past, to of sales the respect comes

reduce So that some our believe of we to costs. been we've able

sales, that guidance revised we organization, quarters. quarter, You'll the coming see and feel improvement in QX really our good as see where second we positive really seasonal that gave you'll and more and about well. actions line in in quarter expecting some QX both we're of throughout and have these bottom We in the the EBITDA taken in and in QX, the efforts, revenue we've especially our strong

Andrew Ranieri

for Got that XXXX. it. And hear right, I right? Mark, you did say EBITDA did positive

Mark Hair

Yes.

we positive So be corner year. should in that we're territory -- turn and next

Operator

next Zimmerman question with from Ryan And BTIG. comes our

Iseult McMahon

Ryan. Izzy is for This on

start to touch out to HOPD just the on ASC rates really reimbursement So both lift great the XXXX. to the settings. and in the for proposed see It's

you the XXXX are guidance about think we going your in drive think help rates not in adoption surgeons will products? the bring proposed of reimbursement as you're but provide finalized So and if you granted, new lift to here, do and

John Treace

of Eli them (sic) proposed Jan [ in anticipate Izzy Yes, go effect and encouraged we're ], and changes They X it's these about year. optimistic November. being really into next John. finalized

way the benefits. final, the several are think now, the already of reimbursed we XX% cases -- the it XX% could that our under to the between reimbursement hospital due for proposed look currently at XXXX that additional APC and we XXXX. see rule we outpatient reimbursed potentially our code. that certain procedures of in Lapidus lower So remaining are with setting somewhere becomes Right cases performed under That to change XX% if along XX% it,

frequently if in a beneficial cost-conscious only and happen. sure, helping settings the see for us ASC with real cases. benefit could currently we access were be for can it the potential technologies where we're our So positive terms doing could ASC also more in more of to being used And as setting, in premium that more this

a any or that And upsides. final. So not really only see we this, reminder yet proposed can't again, downside they're to

Mark Hair

whether indications or And heard And some respect not from to Mark. Yes. they access to this we've some certain is pricing, ASCs. customers have with

that they access products have might the of would well. our absolutely this full And to have alleviate concerns some as of line to so

that we it's And recognize by not proposed, we it. feel it's only So yet encouraged final.

hopefully be we'll to quarters. about talk in future so this And able

Iseult McMahon

Got you think That's surgeon we as do heard have it. XXX on about introductions comments think them new far, that the year half there new forward? first the you so of so helpful. through But for sustainable received that I increase And that XXX, pretty product doctors tracking the it's and a you've the training that that? your is far. well feedback year in opportunity is Or any to the going then

Mark Hair

we of Mini-Adductoplasty, space and reach surgeons. MIS only our of opportunity MIS of of our before. including then surgeon adds Yes. That's a get we're had osteotomy current a great resonating Not question. some seems customers, lot of that it's like is then of across this, MIS platforms, indication, minimally year. training lot said, on Again, that are a we haven't definitely we've theme given surgeon on next I new them well. John new any our is guidance about early some invasive the giving think our specifically never and tell can combining really but that a trainings really our Micro-Lapiplasty excited level to our systems with And our next year. osteotomy solutions us inviting you reasonable to played is But outside any as focused I and where We've base surgeons, a customer if procedures,

procedure another. versus of And John one a mentioned, to type as just some surgeons have bias

osteotomies. are bias so a that out lot surgeons of to have there a And there

with lot them, for interaction and this really opens new And door up a had so haven't of a us. we

interest well. feeling so right you seen number next really trends that not any the early year's if as good And about we're we've the we're now, is definitely giving but indication,

Operator

comes Richard question Securities. Newitter Truist And our next with from

Benjamin Goldstein

for on Ben is me? you hear This Can Rich.

Mark Hair

can. We

Benjamin Goldstein

right. All Yes.

in most through And of call, a be launches you products the share? wondering else you on these might earlier like mentioned to anything launch these needle-moving? to of new think XX you'd I the So was pipeline XXXX. which

John Treace

going enter. MIS I real and Yes. then at predominantly it's surgeon are like us products base. category Ben, one It's products opportunity surgeon having also is incremental going a new Obviously, new lot We look a platforms solutions one And for in said, provide things. X,XXX-plus osteotomies. exciting new as it's to to them Medical our it around this as to they think, do to Mark osteotomy John. of Treace osteotomy do our the haven't take to to a osteotomy unique X Lapiplasty be, users wrap used opportunity those that all users through well. Lapiplasty offerings our because our other And attract SpeedPlate then complementary plus

back categories. be serve our accelerate Kind that the this I at correction we penetration and midfoot before be call, help incremental bunion the in the core of those And into more more one And they'll straightforward regarding and would as the the giving that Adductoplasty fully that second offerings. procedure today. our new be their And the markets lines our done like into in really group well beyond would of Hammertoe time, tell procedures those target more service that that the cases of products we allow to details those reps the product procedures needs not technology base our X complex we're the and other a these platforms can or would core to about covered procedure. one-stop but -- you on product with as shop and fall tie we've comprehensive become X third

what I can future closer that's to much sharing those you and as more But guys calls for now, pretty give we they come to look say. fruition. forward So more detail on in

Operator

Parsons next question from with Harrison our Stephens. comes And

Harrison Parsons

Mark, on commercial Lapiplasty just on the wondering you was CMS of the increase if more break from I more price increases. this think also, premium versus I ASP in wanted out for Harrison Or your should proposed blended base specifically if products? all exposure you I was And market the we then I expect could as wanted is CMS? George. to to circle it on back take procedure? wondering a

Mark Hair

Yes.

So Harrison. for the Thanks this question. is Mark,

start where me is this looking there. don't to price. I we're really an with the part take Let first opportunity think

surgeons. for We have fixation a really nice portfolio offerings of

some newer generation using and We products earlier have they generation our are They've have clinical know SpeedPlate. also work, We that been studies. we fantastic. some that

a And nice price customers. have so we surgeon points of for at our these lot come offering. A different

think setting. lot really same or other do whether it's hospital And what is it it's well. greater that whatever very are so I common And is they're offer environment of complementary the products corrected. And performed also as bunion will a in, at access the just ASC allow that time procedures a we in

our now not an it more us easier makes right opportunity it think gives to our to accessible as it so I from viewing but to other But surgeons. maybe just products it prices, and an we're raise well. customer benefit And opportunity complementary as

of pay. to part fall -- some We -- of their in line other more question tend The exposure follow what know CMS is the commercial that has. they was the or to

most the at So higher now. in little a anyway rate currently, bit -- we but believe payers right and cases, commercial are reimbursing

one for or whatever So I just the accessible our hospitals a other, creates ASCs. in way exposure from know bit that products or definitely don't CMS it it makes perspective little setting but Medicare a more

John Treace

majority were asking about of maybe And are our commercial patients Harrison, I of mix think commercial you pay. pay. The

Harrison Parsons

limited you you good. full And sounds the of quarter. your market year? your if about impact terms osteotomy the wondering for Yes, I then release fourth want MIS ask to quantify it. guidance the in that of was I Got in the financial could expect did

Mark Hair

make because fashion. in thanks do that's launch it for sure great it's that we tend to No, want asking people. products, we a to really for question, limited and I When it very clear a

impact it the upside full surgeons have first out to it patients. them, for have So I wouldn't already the to but will the all. as available have a their move the numbers. bite really QX. already options and in treat any not into that it's baked as but it's the we'll nice have some -- be hands We'll say in how is be having at suite going to material on options the quarter. at of put into late be far in them products will needle apple more these there. fourth It additional quarter, don't quarter Maybe It may we the see really have trainings and surgeon to a nice

are should increase So or expectations any to for quarter. fourth there the I don't there what change out think be

Operator

And closing it the back to turn now would I this question-and-answer Cervantes for Vivian to session. remarks. concludes like

Vivian Cervantes

operator. look concludes call, next the you, This XXXX. behalf to joining following and of close thanks, the forward for us today. everyone, we of our Treace On of update our quarter Thank Medical, third

Operator

This does conclude program. the

You may now disconnect.

Treace Medical Concepts (TMCI) 6 Aug 242024 Q2 Earnings call transcript